Dr. Constance Zou MD

Headshot of a smiling woman with long dark hair wearing a taupe top against a light background.

I am a board-certified psychiatrist with training from Columbia, Yale, the Medical University of South Carolina, and the National Institute of Mental Health. Many of the individuals I work with are navigating depression, anxiety, bipolar disorder, trauma, intrusive thoughts, sleep difficulties, or the emotional strain of medical illness or reproductive life transitions. Often, they arrive feeling unsure of where to begin or worried they are not making sense. What they truly want is to feel seen, understood, and supported by someone who can meet their complexity with clarity and care.

I offer medication management with supplementary therapy, specializing in nuanced and overlapping mental health conditions. My clinical decisions are grounded in nearly two decades of neuroscience and psychopharmacology research, which informs a thoughtful, individualized approach to treatment. I provide extended intake sessions to ensure you have the time and space to share your story in full. I also offer evening and weekend appointments to make it easier to prioritize your mental health alongside life’s other responsibilities.

You do not need to have a clear diagnosis or the perfect words to start this process. Often, the experiences that are most difficult to express are the ones that need the most attention. I create a calm, supportive space where we can explore your concerns together, at a pace that feels right for you. Whether you are feeling ready to begin or simply wondering whether this might help, I welcome you to reach out when the time feels right.

Education

MD – Yale School of Medicine, New Haven, CT
MA in Bioethics – New York University, New York, NY
BA in Biology, Summa Cum Laude, Phi Beta Kappa – Columbia University, New York, NY

Residency and Fellowship

General Psychiatry – Medical University of South Carolina, Charleston, SC and National Institute of Mental Health, Bethesda, MD
Clinical Fellowship in Psychiatry – National Institute of Mental Health, Bethesda, MD

Board Certification

American Board of Psychiatry and Neurology

Conference Presentations

Zou CX, Ben-Dor R, Guerrieri GM, Martinez PE, McCluggage P, Ben-Dor Y, Nieman LK, Wakim P, Rubinow DR, Schmidt PJ. Depression and Menopausal Transition: a Prospective Longitudinal Study. Poster, Society of Biological Psychiatry 2023 April 26 th -29 th , San Diego, CA.

Zou CX, Becker JE, Phillips AT, Krumholz HM, Miller JE, Ross JS. Impact of FDAAA on Registration, Results Reporting and Publication of Neuropsychiatric Clinical Trials Supporting FDA New Drug Approval, 2005-2014. Podium Presentation, 2017, Eighth Peer Review Congress, Chicago, IL

Basturk O, Wei JJ, Kong J, Zou X*, Peng Y, Melamed J, Lee P. MicroRNA Expression in Androgen Independent and Metastatic Prostate Cancer. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2008, 2008 March 1-7. Denver, CO

Newman KK, Wang BY, Cetin N, Ye H, Zou X*, Lee P, Melamed J. Differential Steroid Hormone Expression in Renal Cell Carcinoma Subtypes. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2009. March 7-13. Boston, MA

Pan LY, Wei JJ, Patwa RR, Ligr M, Jain S, Zou XY*, Daniels G, Li YR, Xu RL, Sun W, Wang ZX, Lee P, Chen F. Androgen Receptor Coactivator p44/Mep50 in Ovarian Cancer. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2010. March 20-26, Washington DC

Peer-Reviewed Publications

Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials 2018 Oct 23;19(1):581

Phillips AT, Desai, NR, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017 July 18:333

Segura MF, Hanniford D, Menendez S, Reavie L, Zou X*, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9.

Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X*, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009 Apr 15;69(8):3332-8.

Shi G, Perle MA, Mittal K, Chen H, Zou X*, Hernando E, Lee P, Wei JJ. J Cell Mol Med. 2008 Oct 13. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med. 13(9B):3898-905 2008 Oct 13.

Peng Y, Li Y, Gellert LL, Zou X*, Wang J, Singh B, Xu R, Chiriboga L, Daniels G, Pan R, Zhang DY, Garabedian M, Schneider R, Wang Z, Lee P. Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med. 2009 Oct 16.

Wang L, Zou X*, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 2009;1(1):62-71.

Ligr M, Li Y, Zou X*, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, Lee P. Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol. 2010 Apr;176(4):1891-900.

Hatcher DL, Daniels G, Lin L, Basturk O, Zou X, Ostrer H, Epithelial and stromal microRNA expression in racial disparity of prostate cancer. J Urology. 2009 April;181(4) Supplement773–774

Mahajan A, Liu Z, Gellert L, Zou X*, Yang G, Lee P, Yang X, Wei JJ. HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol. 2010 May;23(5):673-81.

Monaco ME, Creighton CJ, Lee P, Zou X*, Topham MK, Stafforini DM. Expression of long-chain fatty acyl-coA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. Transl Oncol. 2010 Apr;3(2):91-8.

Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X*, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P.Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011 Jul;128(2):391-400.

Wang L, Zou X*, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. 2009;1(1):62-71.

* Published under previous legal name Zou, Xuanyi